

S100B Protein as a Post-traumatic Biomarker for Prediction of Brain Death in Association With Patient Outcomes

Moslem Shakeri^{1,*}, Atta Mahdkhah¹, Farid Panahi²

¹Department of Neurosurgery, Tabriz University of Medical Sciences, Tabriz, IR Iran

²Neurosciences Research Center, Tabriz University of Medical Sciences, Tabriz, IR Iran

*Corresponding author: Moslem Shakeri, Department of Neurosurgery, Tabriz University of Medical Sciences, Tabriz, IR Iran. Tel: +98-4113340830, Fax: +98-4113340830, E-mail: moslemshakeri@yahoo.com.

Received: October 12, 2012; **Revised:** February 26, 2013; **Accepted:** March 25, 2013

Background: S100B is a calcium-binding protein, belonging to the S100 family proteins which are characterized by their high solubility and, currently, comprises 21 members which are expressed in a cell-specific manner. If we can predict the possibility of definite brain death after brain injury, we will rescue some organs of body to transplant proposes.

Objectives: In this regard, our study focused on the S100B protein value in predicting brain death after head trauma. In this study, the use of serum level of protein S100, 24 hours after trauma has been considered as a reliable index for predicting brain death.

Patients and Methods: 72 patients (50 male and 22 female) aged 5 - 80 years old (median 40 ± 17.72 years) with severe head traumas (GCS ≤8) were recruited in this cross-sectional study. Glasgow Coma Scale (GCS) and computed tomography (CT) scan findings were recorded for all patients, and then a single 5mL blood sample was obtained from each patient on admission, after 48 hours and a week later or after brain death to determine the level of S100B protein.

Results: Primary and the last GCS of patients had a predictive value in determining brain death ($P < 0.0005$), also there was a significant correlation between GCS and level of S100B protein. There was a significant correlation between CT scan findings and S100B protein only after 48 hours of trauma.

Conclusions: Changes in S100B protein, especially the levels of this dimer 48 hours after trauma can be used as marker to predict brain death. Alongside other known prognostic factors such as age, GCS and diameters of the pupils, however, this factor individually can not conclusive predict the patient's clinical course and incidence of brain death. However, it is suitable to use GCS, CT scan, clinical symptoms and biomarkers together for a perfect prediction of brain death.

Keywords: Posttraumatic Brain Death; Predictor; Biomarkers; S100B Protein; Outcome

1. Introduction

Brain injury is the third most common cause of mortality in the world. In spite of progress in monitoring and imaging studies, definite and correct prediction of brain death after brain trauma is not possible. Many studies have been done to make definite predictions of brain death after trauma (1 - 3). Prediction of brain death will enable us to save body organs if transplantation is considered. (4). Brain death is evaluated using confirmatory tests (Table 1) however misdiagnosis is possible if drug intoxication, hypothermia and locked-in syndrome are not recognized (4).

Although many scoring systems including Glasgow Coma Scale Score (GCSS) (5), physiologic scoring systems e.g. Revised Trauma Score (RTS) (6) and Trauma Scoring and Injury Severity Score (TRISS) (7), have already been developed for assessment of injuries, however they are less valuable in prediction of outcome in traumatic brain

injury (4). To overcome the possibility of misdiagnoses of brain death on the base of clinical criteria, biomarkers have attracted the researchers' attention (8). Some of these markers have been proposed for the monitoring of brain damage, e.g. Neuron Specific Enolase (NSE), Creatine Kinase isoenzyme BB, 14-3-3 protein, myelin basic protein, Tau protein, polyamines and S100B protein (9-13). One of the brain specific biomarkers found in the past decades is S100B, expressed and produced by astrocytes in vertebrate brains (14). It is one of the calcium-binding proteins characterized by their high solubility and includes 21 members with cell-specific expression. In the CNS, the astrocytes are the major cells producing S100B protein in gray matter, and oligodendrocytes are the predominant S100B in protein producing cells in white matter (15). S100B protein can be produced in other cells such as adipocytes, chondrocytes, lymphocytes, bone marrow

Implication for health policy/practice/research/medical education:

Identifying a new biomarker to predict posttraumatic brain death can have basic and practical results and can also lead to new understandings of the process of brain death.

Copyright © 2013, Kashan University of Medical Sciences; License Kowsar Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

and melanoma cells (16). These data lead to controversy about the S100B protein and its dependency to brain injury (17-21). All authors agree that increasing levels of S100B within 12 hours after traumatic brain injury and cardiac surgery may correlate well with a poor outcome (22-24).

2. Objectives

This study focuses on the level of serum S100B after brain injury at the time of admission, 48 hours and a week later, or when the patient is labeled as brain death, to predict outcome of patients after traumatic brain injury.

3. Patients and Materials

Seventy-two trauma patients in the age range of 5 to 80 years and GCSS \leq 8 admitted to trauma and ICU wards of Imam Hospital were enrolled in this cross-sectional study, after ethics committee approval. All patients were examined within 6 hours of their admission. Those patients with severe abdominal and chest injuries, or limb fractures, those under the age of 5, those who died within 24 hours of their admission, and finally all of those with a history of trauma, resuscitation, acidosis, hypotension, hypoxia, neurological diseases and spinal cord injuries were excluded from the study. All selected patients were examined by a neurosurgery resident, unaware of their selection, on admission, discharge or death. On the base of their condition, the patients were sedated, intubated and/or mechanically ventilated. Surgical decompression of hematoma and induction of barbiturate coma were

considered if needed. Also, the patients were treated for effective control of cerebral perfusion pressure according to neurointensive guidelines (25). Initial CT scans were performed for all patients and evaluated by a radiologist who was not aware of the patient's profile. The following variables were recorded for each of the patients by a junior resident; age, sex, kind of trauma (road traffic accidents, falls from heights and strife), a history of specific diseases, the time of referral and hospital admission, length of hospital stay, GCS at admission and discharge or death, status of pupils, types of treatment (surgery-conservative), and neural status during hospitalization (improved - brain death). A single 5mL blood sample was obtained via an intravenous catheter from each patient on admission (first blood sample was taken 2 ± 0.5 hours after admission), 48 hours later, a week later or after brain death to determine the level of S100B protein. Serum samples were centrifuged, separated and stored at -70°C until the analysis, and once gathered, samples from all patients were analyzed by enzyme immunoassay technique with a high degree of sensitivity. Doses greater than 0.5 micrograms per liter were considered as elevated and those above 0.15 micrograms per liter were normal and the boundary between these two values was considered. All data are expressed as mean \pm SD, percentage and frequency. Obtained data were analyzed by using one-way ANOVA, Chi-square test, non-parametric Wilcoxon technique, Pearson correlation test, Repeated measures design test and Kolmogorov-Smirnov test. In all investigated cases, Statistical significance was set at 0.05.

Table 1. Clinical Criteria for Brain Death

Coma
Absence of motor responses
Absence of pupillary responses to light and pupils at midposition with respect to dilatation (4 - 6 mm)
Absence of corneal reflexes
Absence of caloric responses
Absence of gag reflex
Absence of coughing in response to tracheal suctioning
Absence of sucking and rooting reflexes
Absence of respiratory drive at a PaCO ₂ that is 60 mmHg or 20 mmHg above normal base-line values ^a
Interval Between Two Evaluations, According to Patient's Age
Term to 2 m old, 48 h
> 2 m to 1 y old, 24 h
> 1 y to < 18 y old, 12 h
\geq 18 y old, interval optional
Confirmatory Tests
Term to 2 m old, 2 confirmatory tests
> 2 m to 1 y old, 1 confirmatory test
> 1 y to < 18 y old, optional
\geq 18 y old, optional

^a PaCO₂ denotes the partial pressure of arterial carbon dioxide

4. Results

Seventy-two patients (50 male and 22 female) aged 5-80 (median 40 ± 17.72 years) with head traumas were recruited in this study.

All patients were divided into two groups according to clinical manifestation:

a) The first group, termed the "improved group", consisted of those who survived during hospitalization and included 42 patients.

b) The second group included those who died during hospitalization and were themselves divided into two categories:

1) The first group died from non-cerebral reasons and included 14 patients.

2) The second included 16 patients who died because of brain death.

In 4 cases with eye trauma, assessment of the pupillary response was not possible. The correlation between pupillary response and S100B protein level at different stages was not significant.

The results of treatment in the three groups was as follows: Craniotomy in improved group was carried out on 6 cases (14.3%) and conservative therapy on 36 patients (87.5%). In the group with death due to non-cerebral reasons, craniotomy was done for 6 (42.9%) and conservative treatment for 8 patients (57.1%). There were 7 cases (46.7%) with craniotomy and 8 cases (53.3%) with conservative treatment in those with brain death, $P = 0.008$, and there was a significant difference in treatment between these three groups. In fact, we had more craniotomy in the group with brain death in comparison with the oth-

er groups. There was no significant difference between patients in their laboratory findings, except in WBCs ($P = 0.003$). The first and the last GCS of the patients had a predictive value in determining brain death ($P < 0.0005$). Association between primary GCS and S100B protein levels at the first hour, 48 hours later and at the final measurement, showed a significant correlation, with $P = 0.02$, $P = 0.007$, $P = 0.006$, respectively. Thus, Pearson correlation coefficients were -0.23, -0.29 and -0.92, respectively which represented a negative association between GCS and protein S100B. Also, a significant correlation was observed between final GCS and protein S100B level at first, 48 hours later and final measurement with $P = 0.027$, $P < 0.0005$ and $P < 0.0005$, respectively. The Pearson correlation coefficient was -0.22, -0.4 and -0.41, which indicated a negative association between the final GCS and protein S100B levels. Comparison of brain CT scan findings based on Marshall Classification with levels of protein S100B measured at three different stages only indicated a significant difference in S100B levels 48 hours after trauma ($P = 0.017$) (Table 2).

Findings in terms of protein S100B levels on admission, after 48 hours and the final protein level between the three groups based on the following table, revealed a significant difference between levels of protein S100B for these three time points with $P < 0.0005$ (Table 3).

Two by two Comparison of the groups showed (Figure 1) that the difference in the first and second blood sample was statistically significant ($P < 0.0005$), but the difference between step one and three was not significant ($P > 0.05$).

Table 2. S100B Protein Levels Compared With Brain CT Scan Grade for the Three Groups

	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	Mean ± SD	P value
S100 first	0.41 ± 1.09	0.64 ± 1.04	0.81 ± 10.38	0.72 ± 1.22	0.99 ± 0.40	0.352
S100 after 48 hours	0.40 ± 0.98	1 ± 0.56	0.94 ± 1.59	1.17 ± 1.95	1.41 ± 0.56	0.017
S100 last	0.48 ± 0.92	0.41 ± 0.75	0.64 ± 1.07	0.84 ± 1.25	0.97 ± 0.45	0.342

Table 3. Comparison of the Initial, 48 Hours Later and the Final Levels of S100B Protein Between the Three Groups

	All Patients, Mean ± SD	Improvement, Mean ± SD	Death, Mean ± SD	Brain Death, Mean ± SD	P value
S100 first	1.13 ± 0.6	0.99 ± 0.45	1.12 ± 0.36	1.01 ± 0.93	0.013
S100 after 48 hours	1.42 ± 0.81	1.04 ± 0.5	1.46 ± 0.51	2.36 ± 0.94	< 0.0005 ^a
S100 last	1 ± 0.58	0.77 ± 0.4	1.08 ± 0.45	1.53 ± 0.73	< 0.0005 ^a

^a P values were significant ($P \leq 0.05$)

5. Discussion

In this study, S100B protein level was assessed as a biomarker to predict brain death in patients with severe head trauma ($GCS \leq 8$), and it was found that S100B protein levels increased in the brain death group, 48 hours after brain trauma. In 2008, Carlos et al. evaluated biological and methodological features of S100B. They noted

that S100B protein is a marker of action or death of astrocytes and oligodendrocytes (26). Hayakata et al. noted that the level of S100B protein increased shortly after a head trauma, and then gradually decreased. In that study there was a significant correlation between increasing S100B protein and intracranial pressure (ICP) elevation (27). Another study in 2000 showed that the level of

S100B protein increased shortly after the occurrence of trauma, in both the improved and brain death groups, but after 3-4 days, it normalized in the former group, but in the brain death group it normalized within 1-6 days and increased then after, for the progressive damage of brain cells (24). In our study ICP was not measured, however the results are different from those for the others. This may be due to the selection of patients with severe head injury. In our study the first blood sample was obtained 2 ± 0.5 hours after trauma. In a Meta-analysis in 2005 it was reported that highest sensitivity and specificity of S100B protein may be achieved if the first sample of blood which determines the level of S100B is obtained within 6 hours after trauma (28). In the present study patients with concomitant severe abdominal and chest injuries and limb fractures were excluded. It seems that skull fractures also may result in increased S100 level. In a study by Savola et al. it was shown that S100 level has a correlation with the severity of brain injury or in other words the severity of trauma. However, it was also found that massive extra-cranial trauma affects the serum levels of S100B protein (29). In the same direction, Uden et al. in their study in 2005 showed that S100 proteins can only be increased in 30% of patients with extremity fractures without brain damage (30). In our study, the level of S100B protein on admission, 48 hours later and at the final measurement was statistically and significantly different between the groups, and the level of S100B in the brain death group was higher than the others. Jang et al. noted the increased levels of S100B protein in patients who died within two weeks of their head trauma. The mean age of their patients was 34 years which is higher than the mean age of ours (mean age of 30.4 years) (31). The average of primary GCS score of patients in the current study was 5 ± 2 . In the improved group it was 5.5 and in the brain death and non-cerebral death group, it was 3. Pelinka et al. studied serum S100 protein in patients with severe head traumas, without having multiple traumas. The average GCS of their patients on admission was 6. In this study, the use of serum level of protein S100, 24 hours after trauma has been considered a reliable index for predicting brain death (32). Nylen et al. in 2008 in Sweden measured the different dimmers of S100 in traumatic patients. The results suggest that all three dimmers of S100 protein increase in trauma patients and their amounts are different, but this difference was not statistically significant. Since measurement of the sub types of S100 protein was not cost effective compared with the S100B dimer (33), we preferred to measure only S100B dimer in our patients. In our study CT scan findings had a significant correlation with S100B protein only after 48 hours ($P=0.01$). Oh et al. noted a significant correlation between MRI and CT scan findings and S100B proteins. There was a negative association between GCS and level of S100B protein; this shows that any patient with a low GCS will have a bad prognosis (34). Similar findings were reported

by the Townend et al. study (35). In a prospective study in 2006 by Korfiatis et al. on 102 patients with severe head trauma, a correlation was found between increased levels of S100 protein and pupillary reaction, brain CT scan report and their improvement after a month.




Figure 1. S100 Levels Between the Three Groups

Based on the results of this study, protein S100B changes and especially the levels of this dimer 48 hours after trauma can be used as a marker to predict brain death, along other known prognostic factors such as age, GCS and diameters of the pupils. However, this factor individually, cannot be conclusive for prediction of the patient's clinical course and brain death. Given the importance of S100B protein, accesses to facilities for its measurement, in hospitals managing brain trauma victims, seems to be necessary.

Authors' Contribution

Shakeri, M. (A, B); Mahdikhah, A. (B, D, E); Panahi, F. (C, F); A: study design, B: data collection, C: statistical analysis, D: data interpretation, E: manuscript preparation, F: literature search.

Financial Disclosure

The authors have declared no potential conflicts of interest.

Financial Disclosure

Research Deputy of Tabriz University of Medical Sciences.

References

- Guidelines for the management of severe head injury. Brain Trauma Foundation, American Association of Neurological Surgeons, Joint Section on Neurotrauma and Critical Care. *J Neurotrauma*. 1996;13(11):641-734.
- Sumas ME, Narayan RK, Grossman GR, Loftus CM. Head Injury. In: Sumas ME, Narayan RK, Grossman GR, Loftus CM, editors. *Principles of Neurosurgery*. Philadelphia: Lippincott-Raven; 1999. p. 117-71.
- Winn HR, Youmans JR. *Youmans Neurological Surgery*. 2004.
- Wijdicks EF. The diagnosis of brain death. *N Engl J Med*.

- 2001;**344**(16):1215-21.
5. Teasdale G, Jennett B. Assessment of coma and impaired consciousness. A practical scale. *Lancet*. 1974;**2**(7872):81-4.
 6. Champion HR, Sacco WJ, Copes WS, Gann DS, Gennarelli TA, Flanagan ME. A revision of the Trauma Score. *J Trauma*. 1989;**29**(5):623-9.
 7. Boyd CR, Tolson MA, Copes WS. Evaluating trauma care: the TRISS method. Trauma Score and the Injury Severity Score. *J Trauma*. 1987;**27**(4):370-8.
 8. Uden J, Astrand R, Waterloo K, Ingebrigtsen T, Bellner J, Reinstrup P, et al. Clinical significance of serum S100B levels in neurointensive care. *Neurocrit Care*. 2007;**6**(2):94-9.
 9. Els T, Bruckmann J, Rohn G, Daffertshofer M, Monting JS, Ernestus RI, et al. Spermidine: A predictor for neurological outcome and infarct size in focal cerebral ischemia? *Stroke*. 2001;**32**(1):43-6.
 10. Green AJ, Thompson EJ, Stewart GE, Zeidler M, McKenzie JM, MacLeod MA, et al. Use of 14-3-3 and other brain-specific proteins in CSF in the diagnosis of variant Creutzfeldt-Jakob disease. *J Neurol Neurosurg Psychiatry*. 2001;**70**(6):744-8.
 11. Ingebrigtsen T, Romner B. Biochemical serum markers of traumatic brain injury. *J Trauma*. 2002;**52**(4):798-808.
 12. Lima JE, Takayanagui OM, Garcia LV, Leite JP. Use of neuron-specific enolase for assessing the severity and outcome in patients with neurological disorders. *Braz J Med Biol Res*. 2004;**37**(1):19-26.
 13. Studahl M, Rosengren L, Gunther G, Hagberg L. Difference in pathogenesis between herpes simplex virus type 1 encephalitis and tick-borne encephalitis demonstrated by means of cerebrospinal fluid markers of glial and neuronal destruction. *J Neurol*. 2000;**247**(8):636-42.
 14. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). *Biochem Biophys Res Commun*. 2004;**322**(4):1111-22.
 15. Steiner J, Bernstein HG, Biela H, Berndt A, Brisch R, Mawrin C, et al. Evidence for a wide extra-astrocytic distribution of S100B in human brain. *BMC Neurosci*. 2007;**8**:2.
 16. Donato R. S100: a multigenic family of calcium-modulated proteins of the EF-hand type with intracellular and extracellular functional roles. *Int J Biochem Cell Biol*. 2001;**33**(7):637-68.
 17. Anderson RE, Hansson LO, Nilsson O, Djalil-Merzoug R, Settergren G. High serum S100B levels for trauma patients without head injuries. *Neurosurgery*. 2001;**48**(6):1255-8.
 18. Anderson RE, Hansson LO, Nilsson O, Liska J, Settergren G, Vaage J. Increase in serum S100A1-B and S100BB during cardiac surgery arises from extracerebral sources. *Ann Thorac Surg*. 2001;**71**(5):1512-7.
 19. Diehl LA, Silveira PP, Leite MC, Crema LM, Portella AK, Billodre MN, et al. Long lasting sex-specific effects upon behavior and S100b levels after maternal separation and exposure to a model of post-traumatic stress disorder in rats. *Brain Res*. 2007;**1144**:107-16.
 20. Harpio R, Einarsson R. S100 proteins as cancer biomarkers with focus on S100B in malignant melanoma. *Clin Biochem*. 2004;**37**(7):512-8.
 21. Jonsson H, Johnsson P, Alling C, Backstrom M, Bergh C, Blomquist S. S100beta after coronary artery surgery: release pattern, source of contamination, and relation to neuropsychological outcome. *Ann Thorac Surg*. 1999;**68**(6):2202-8.
 22. Janigro D. A response to 'Cerebral and extracerebral release of protein S100B in cardiac surgical patients', Snyder-Ramos SA, Gruhlke T, Bauer H, Bauer M, Luntz AP, Motsch J, Martin E, Vahl CF, Missler U, Wiesmann M and Bottiger BW, *Anaesthesia* 2004; **59**: 344-9. *Anaesthesia*. 2004;**59**(11):1149-50.
 23. Missler U, Orłowski N, Notzold A, Dibbelt L, Steinmeier E, Wiesmann M. Early elevation of S-100B protein in blood after cardiac surgery is not a predictor of ischemic cerebral injury. *Clin Chim Acta*. 2002;**321**(1-2):29-33.
 24. Raabe A, Seifert V. Protein S-100B as a serum marker of brain damage in severe head injury: preliminary results. *Neurosurg Rev*. 2000;**23**(3):136-8.
 25. Rainey T, Lesko M, Sacho R, Lecky F, Childs C. Predicting outcome after severe traumatic brain injury using the serum S100B biomarker: results using a single (24h) time-point. *Resuscitation*. 2009;**80**(3):341-5.
 26. Goncalves CA, Leite MC, Nardin P. Biological and methodological features of the measurement of S100B, a putative marker of brain injury. *Clin Biochem*. 2008;**41**(10-11):755-63.
 27. Hayakata T, Shiozaki T, Tasaki O, Ikegawa H, Inoue Y, Toshiyuki F, et al. Changes in CSF S100B and cytokine concentrations in early-phase severe traumatic brain injury. *Shock*. 2004;**22**(2):102-7.
 28. Lomas JP, Dunning J. Best evidence topic report. S-100b protein levels as a predictor for long-term disability after head injury. *Emerg Med J*. 2005;**22**(12):889-91.
 29. Savola O, Pyhtinen J, Leino TK, Siitonen S, Niemela O, Hillbom M. Effects of head and extracranial injuries on serum protein S100B levels in trauma patients. *J Trauma*. 2004;**56**(6):1229-34.
 30. Uden J, Bellner J, Eneroth M, Alling C, Ingebrigtsen T, Romner B. Raised serum S100B levels after acute bone fractures without cerebral injury. *J Trauma*. 2005;**58**(1):59-61.
 31. Jang Woo Youl, Kim Jae Hyoo, Joo HP, Lee Jung Kil, Kim Tae Sun, Kim Soo Han. Serum S-100B Protein as a Prognostic Factor in Patients with Severe Head Injury. *J Korean Neurosurg Soc*. 2006;**39**:271-276.
 32. Pelinka LE, Toegel E, Mauritz W, Redl H. Serum S100 B: a marker of brain damage in traumatic brain injury with and without multiple trauma. *Shock*. 2003;**19**(3):195-200.
 33. Nysten K, Ost M, Csajbok LZ, Nilsson I, Hall C, Blennow K, et al. Serum levels of S100B, S100A1B and S100BB are all related to outcome after severe traumatic brain injury. *Acta Neurochir (Wien)*. 2008;**150**(3):221-7.
 34. Oh EJ, Kim YM, Jegal DW, Kahng J, Park YJ, Han K. Diagnostic value of Elecsys S100 as a marker of acute brain injury in the emergency department. *J Clin Lab Anal*. 2007;**21**(6):387-92.
 35. Wunderlich MT. Head injury outcome prediction in the emergency department: a role for protein S-100B? *J Neurol Neurosurg Psychiatry*. 2003;**74**(6):827-8.